Johnson & Johnson, U.S. government expand pact to support next phase of COVID-19 vaccine R&D

(Reuters) - Johnson & Johnson and the U.S.

Reuters November 15, 2020 00:05:09 IST
Johnson & Johnson, U.S. government expand pact to support next phase of COVID-19 vaccine R&D

COVID-19 vaccine R&D" src="https://images.firstpost.com/wp-content/uploads/reuters/11-2020/15/2020-11-14T174541Z_1_LYNXMPEGAD0ET_RTROPTP_2_HEALTH-CORONAVIRUS-VACCINE.jpg" alt="Johnson Johnson US government expand pact to support next phase of COVID19 vaccine RD" width="300" height="225" />

(Reuters) - Johnson & Johnson and the U.S. Department of Health and Human Services have expanded an agreement to support the next phase of COVID-19 vaccine candidate research and development, the company said on Saturday.

Under the agreement the company will commit approximately $604 million and the HHS Department's Biomedical Advanced Research and Development Authority will commit about $454 million to support the Phase 3 ENSEMBLE trial evaluating Janssen's investigational COVID-19 vaccine candidate as a single dose in up to 60,000 volunteers worldwide, the company said in a statement

(Reporting by Sabahatjahan Contractor in Bengaluru; Editing by Matthew Lewis)

This story has not been edited by Firstpost staff and is generated by auto-feed.

Updated Date:

TAGS:

Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.

also read

Wall Street climbs on Cisco, Disney's upbeat results
Business

Wall Street climbs on Cisco, Disney's upbeat results

By Medha Singh and Shivani Kumaresan (Reuters) - Wall Street gained on Friday as Disney and Cisco's upbeat results brought the focus back to corporate earnings at the end of a volatile trading week that saw record surges in coronavirus cases and increased hopes of a working vaccine.

Gold jumps 1% on mounting pandemic, vaccine worries
Business

Gold jumps 1% on mounting pandemic, vaccine worries

By Sumita Layek (Reuters) - Gold gained as much as 1.1% on Friday as rising global coronavirus infections re-ignited concerns about the economic toll from the pandemic, while scepticism over the reach of a potential COVID-19 vaccine further boosted the safe-haven metal. Spot gold rose 0.8% to $1,890.81 per ounce by 11:33 a.m